Table 3.
Baseline Characteristics and Outcomes of 957 HIV/HCV-Coinfected Patients Analyzed to Assess the Ability of Transient Elastography to Predict Outcomes, 634 of Whom Were Randomly Assigned to an Estimation Cohort and 323 to a Validation Cohort
| Variable | Estimation Cohort n = 634 | Validation Cohort n = 323 | Total N = 957 |
|---|---|---|---|
| Baseline variables | |||
| Male sex, n (%) | 483 (76.2) | 263 (81.4) | 746 (78.0) |
| Age, years, median (IQR) | 44 (41–48) | 44 (40–48) | 44 (41–48) |
| HIV acquired by injection drug use, n (%) | 506 (79.8) | 261 (80.8) | 767 (80.1) |
| CDC clinical category C, n (%) | 240 (37.9) | 133 (41.2) | 373 (39.0%) |
| cART, n (%) | 547 (86.3) | 284 (87.9) | 831 (86.8) |
| HIV-RNA <50 copies/mL, n (%) | 457 (72.1) | 243 (75.2) | 700 (73.1) |
| CD4+ T cells/µL, median (IQR) | 432 (254–625) | 429 (273–621) | 430 (261–624) |
| HCV genotype 1, n (%) | 385 (60.7) | 195 (60.4) | 580 (60.6) |
| Liver stiffness, kPa, median (IQR) | 8 (6–11) | 8 (6–14) | 8 (6–12) |
| Follow-up variables | |||
| Follow-up, years, median (IQR) | 5.3 (2.7–6.9) | 5.3 (2.5–7.0) | 5.3 (2.7–6.9) |
| New AIDS-defining condition, n (%) | 30 (4.7) | 19 (5.9) | 49 (5.1) |
| Liver decompensation, n (%) | 44 (6.9) | 22 (6.8) | 66 (6.9) |
| Ascites | 29 | 18 | 47 |
| Other | 18 | 6 | 24 |
| Hepatocellular carcinoma, n (%) | 12 (1.9) | 7 (2.2) | 19 (2.0) |
| Death, n (%) | 45 (7.1) | 21 (6.5) | 66 (6.9) |
| Liver-related | 14 | 9 | 23 |
| AIDS-related | 4 | 1 | 5 |
| Nonliver-related, non-AIDS-related | 25 | 8 | 33 |
| Unknown | 2 | 3 | 5 |
Abbreviations: AIDS, acquired immune defficiancy syndrome; cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; RNA, ribonucleic acid.